Manuel Ruiz-Borrego

15PUBLICATIONS
198CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPsychosocial aspects of childbirth and perinatal mental healthReproduction
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|May 26, 2026
Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial.

|Mar 06, 2026
UGT2B17 as a predictive biomarker of complete pathological response in HER2 + breast cancer.

Ana Gil-Torralvo, M Ángeles Domínguez-Cejudo, Sonia Molina-Pinelo

|Dec 12, 2025
Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer.

Miguel Martín, Ángel L Guerrero-Zotano, María E Pérez-López

|Aug 11, 2025
Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.

Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego

|Jul 09, 2025
Breastfeeding After Hormone Receptor-Positive Breast Cancer: Results From the POSITIVE Trial.

Fedro A Peccatori, Samuel M Niman, Ann H Partridge

|Jul 09, 2025
Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.

Yash N Agrawal, Aranzazu Fernández-Martínez, Miguel Gil-Gil

Pageof 3

Frequent Collaborators

7 joint publications

Miguel Martin

6 joint publications

Begoña Bermejo de Las Heras

6 joint publications

Jesus Herranz

6 joint publications

Angel L Guerrero-Zotano